|
|
||||||||




* Department of Biodefense, Graduate School of Medical Sciences,
School of Nursing, and
Animal Center, Nagoya City University, Nagoya, Japan;
Choju Medical Institute, Fukushimura Hospital, Toyohashi, Japan; and
¶
National Institute for Longevity Sciences, Ohbu, Japan
Carboxypeptidase R (CPR) is a heat-labile enzyme found in serum in addition to stable carboxypeptidase N. CPR cleaves the C-terminal basic amino acids, arginine and lysine, from inflammatory peptides such as complement C3a and C5a, bradykinin, and enkephalin. This enzyme is generated from procarboxypeptidase R (proCPR), also known as thrombin-activatable fibrinolysis inhibitor, following cleavage by proteolytic enzymes such as thrombin, plasmin, and trypsin. We generated proCPR-deficient mice by knocking out exons 4 and 5 of the proCPR gene, which are regarded as essential for CPR function. At LPS challenge, there was virtually no difference in lethality among proCPR+/+, proCPR+/, and proCPR/ mice. However, challenge with cobra venom factor, which can activate and deplete almost all complement in vivo, induced a lethal effect on proCPR/ mice following LPS sensitization which up-regulates C5a receptor expression. In contrast, proCPR+/+ and proCPR+/ mice were able to tolerate the cobra venom factor challenge with the limited dose (30 U). Although carboxypeptidase N plays a role in inactivation of inflammatory peptides in vivo, CPR may also be important in the regulation of hyperinflammation.
This article has been cited by other articles:
![]() |
M. E. Meltzer, C. J.M. Doggen, P. G. de Groot, J. C.M. Meijers, F. R. Rosendaal, and T. Lisman Low thrombin activatable fibrinolysis inhibitor activity levels are associated with an increased risk of a first myocardial infarction in men Haematologica, June 1, 2009; 94(6): 811 - 818. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. L. Mueller-Ortiz, D. Wang, J. E. Morales, L. Li, J.-Y. Chang, and R. A. Wetsel Targeted Disruption of the Gene Encoding the Murine Small Subunit of Carboxypeptidase N (CPN1) Causes Susceptibility to C5a Anaphylatoxin-Mediated Shock J. Immunol., May 15, 2009; 182(10): 6533 - 6539. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. B. Boffa, D. Maret, J. D. Hamill, N. Bastajian, P. Crainich, N. S. Jenny, Z. Tang, E. M. Macy, R. P. Tracy, R. F. Franco, et al. Effect of single nucleotide polymorphisms on expression of the gene encoding thrombin-activatable fibrinolysis inhibitor: a functional analysis Blood, January 1, 2008; 111(1): 183 - 189. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. O. Mosnier, X. V. Yang, and J. H. Griffin Activated Protein C Mutant with Minimal Anticoagulant Activity, Normal Cytoprotective Activity, and Preservation of Thrombin Activable Fibrinolysis Inhibitor-dependent Cytoprotective Functions J. Biol. Chem., November 9, 2007; 282(45): 33022 - 33033. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. M. Ravindranath, M. Goto, O. Iqbal, M. Florian-Kujawski, D. Hoppensteadt, R. Hammadeh, M. M. Sayeed, and J. Fareed Plasma Thrombin Activatable Fibrinolysis Inhibitor and Tissue Factor Pathway Inhibitor Changes Following Sepsis Clinical and Applied Thrombosis/Hemostasis, October 1, 2007; 13(4): 362 - 368. [Abstract] [PDF] |
||||
![]() |
T. Nishimura, T. Myles, A. M. Piliposky, P. N. Kao, G. J. Berry, and L. L. K. Leung Thrombin-activatable procarboxypeptidase B regulates activated complement C5a in vivo Blood, March 1, 2007; 109(5): 1992 - 1997. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Renckens, J. J. T. H. Roelofs, S. A. J. ter Horst, C. van 't Veer, S. R. Havik, S. Florquin, G. T. M. Wagenaar, J. C. M. Meijers, and T. van der Poll Absence of Thrombin-Activatable Fibrinolysis Inhibitor Protects against Sepsis-Induced Liver Injury in Mice J. Immunol., November 15, 2005; 175(10): 6764 - 6771. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |